Matthew W D Perry - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Matthew W D Perry

Showing results (21-30 of 25) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 25 results.

Journal of Medicinal Chemistry|May 19, 2017

Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled AdministrationMatthew W D Perry, Karin Björhall, Britta Bonn, et al.

Journal of Medicinal Chemistry|June 1, 2018

Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ InhibitorsNils Pemberton, Mickael Mogemark, Susanne Arlbrandt, et al.

Journal of Medicinal Chemistry|June 3, 2021

Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of AsthmaMatthew W D Perry, Karin Björhall, Peter Bold, et al.

Nature Chemical Biology|December 24, 2005

Monocarboxylate transporter MCT1 is a target for immunosuppressionClare M Murray, Raymond Hutchinson, John R Bantick, et al.

Nature Communications|March 25, 2026

A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degraderMonica C Rodrigo-Brenni, Jasper C Komen, Ghaith M Hamza, et al.

Pageof 3

Search research articles

Showing results (21-30 of 25) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 25 results.

Journal of Medicinal Chemistry|May 19, 2017

Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled AdministrationMatthew W D Perry, Karin Björhall, Britta Bonn, et al.

Journal of Medicinal Chemistry|June 1, 2018

Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ InhibitorsNils Pemberton, Mickael Mogemark, Susanne Arlbrandt, et al.

Journal of Medicinal Chemistry|June 3, 2021

Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of AsthmaMatthew W D Perry, Karin Björhall, Peter Bold, et al.

Nature Chemical Biology|December 24, 2005

Monocarboxylate transporter MCT1 is a target for immunosuppressionClare M Murray, Raymond Hutchinson, John R Bantick, et al.

Nature Communications|March 25, 2026

A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degraderMonica C Rodrigo-Brenni, Jasper C Komen, Ghaith M Hamza, et al.

Pageof 3